RT Journal Article
SR Electronic
T1 Changes in Oxygen Saturation During Fiberoptic Bronchoscopy: High-Flow Nasal Cannula versus Standard Oxygen Therapy
JF Respiratory Care
FD American Association for Respiratory Care
SP 727
OP 733
DO 10.4187/respcare.10598
VO 68
IS 6
A1 Pedro Pablo Arias-Sanchez
A1 Gabriela Ledesma
A1 Johana Cobos
A1 Hugo Tirape
A1 Betzy Jaramillo
A1 Jeimmy Ruiz
A1 Lucia Pacheco
A1 Juan Martinez
A1 Remigio Maldonado
A1 Luis Andrade
A1 Omar Bustamante
A1 Hernan Aguirre-Bermeo
YR 2023
UL http://rc.rcjournal.com/content/68/6/727.abstract
AB BACKGROUND: Hypoxemia is a relatively common complication in stable patients during fiberoptic bronchoscopy (FOB). To prevent this complication, high-flow nasal cannula (HFNC) has been described as an alternative to standard oxygen therapy. However, the advantages of HFNC over standard oxygen therapy in acute care patients receiving supplemental oxygen before FOB performed with an oral approach are unknown.METHODS: We conducted an observational study that involved subjects with a presumptive diagnosis of pneumonia and a clinical indication for a bronchial aspirate sample. The type of oxygen support (standard oxygen therapy vs HFNC) was selected according to availability. The oxygen flow in the HFNC group was 60 L/min. In both groups, the FIO2 was set at 0.40. Hemodynamic, respiratory dynamics, and gas exchange data were collected at baseline, before, during, and 24 h after FOB.RESULTS: Forty subjects were included, 20 in each group (HFNC and standard oxygen therapy). The study was performed on day 5 of hospitalization in the HFNC group and on day 4 in the standard oxygen therapy group (P = .10). No significant between-group differences in baseline characteristics were observed. HFNC vs standard oxygen therapy was associated with a smaller decrease in SpO2 levels during the procedure (94% vs 90%; P = .040, respectively) and with less variation between the last SpO2 measured before FOB and the lowest SpO2 during FOB (Δ SpO2): 2% versus 4.5% (P = .01, respectively).CONCLUSIONS: In acute subjects who required oxygen support before FOB, the use of HFNC during FOB with an oral approach was associated with a smaller decrease in SpO2 and lower Δ SpO2 compared with standard oxygen therapy.